U.S. Mortgage REITs Stock News

Xenon Pharmaceuticals has announced that it recently presented multiple oral and poster sessions at the American Academy of Neurology Annual Meeting, featuring late-breaking Phase 3 X-TOLE2 results for azetukalner in focal onset seizures alongside long-term efficacy, safety, and real-world data, as well as preclinical NaV1.1 program findings in Dravet syndrome. These comprehensive datasets on azetukalner’s clinical performance and real-world use could shape how physicians, regulators, and...

Turning Point Brands recently faced pressure after the FDA moved to limit fast-tracking of its nicotine product PMTA applications and a law firm began investigating disclosures following lowered guidance tied to challenges in its Modern Oral nicotine pouch business. While these developments have raised questions about growth and regulatory visibility in a key segment, they have come against a backdrop of what had been described as strong overall financial performance and expanding modern...

American Public Education (APEI) is back in focus after two key developments: a top ranking from Zacks backed by higher earnings projections, and a new tuition grant partnership between American Military University and the Military Officers Association of America. See our latest analysis for American Public Education. The recent uptick in sentiment around higher earnings projections and the AMU–MOAA tuition grant partnership sits alongside strong share price momentum, with a 30-day share...

Atlas Energy Solutions stock snapshot after recent performance shifts Atlas Energy Solutions (AESI) has seen mixed share performance lately, with a 1 day gain of 1.68% contrasting with declines over the past week and month, as well as a positive move in the past 3 months. See our latest analysis for Atlas Energy Solutions. At a share price of $11.51, Atlas Energy Solutions shows mixed momentum, with a recent 1 day share price return of 1.68% against weaker 7 and 30 day returns. The year to...

The recent de-escalation of the U.S.–Iran conflict, which eased market volatility and improved risk appetite, helped lift Cadence Design Systems (CDNS), with the stock moving 3.7% higher in the latest session. See our latest analysis for Cadence Design Systems. That move comes after a softer run, with a 90 day share price return of a 14.15% decline and a year to date share price return of a 9.47% decline. However, the 1 year total shareholder return of 10.63% still points to longer term gains...

Recent Performance Context for NextEra Energy NextEra Energy (NEE) has quietly attracted investor attention after a period of solid share price performance, with returns over the past month, past 3 months and year all in positive territory. For investors tracking utilities and clean power, this recent run creates a natural moment to reassess what the current numbers imply. The stock last closed at US$94.48, with a market value of about US$196.4b. See our latest analysis for NextEra...

Science Applications International (NasdaqGS:SAIC) has added Paul Eremenko and retired Navy Admiral Michael Rogers to its Board of Directors. Eremenko brings a background in AI and advanced technology integration, while Rogers adds experience from senior cybersecurity and intelligence roles. The appointments expand board expertise in areas that are central to SAIC's work with defense, federal, and technology focused customers. Science Applications International, traded as NasdaqGS:SAIC, is...

What is moving Flutter Entertainment stock right now? Flutter Entertainment (NYSE:FLUT) is in focus after a combination of events, including an ongoing multi billion dollar buyback, a reduced analyst outlook for U.S. online gaming, and a large stake build by investor Kenneth Dart. See our latest analysis for Flutter Entertainment. At a share price of $105.25, Flutter’s recent 1 day and 90 day share price returns of 3.89% decline and 51.11% decline sit alongside a 1 year total shareholder...

Power Integrations (POWI) has been drawing attention after recent share price moves, with the stock last closing at US$54.54. Investors are weighing this against its reported US$443.504 million revenue and US$22.093 million net income. See our latest analysis for Power Integrations. The recent 21.01% 1 month share price return and 31.39% 3 month share price return suggest momentum has picked up. However, the 3 year total shareholder return of 29.24% and 5 year total shareholder return of...

American Healthcare REIT, Inc. has already amended its primary credit facility and launched a US$1.75 billion at-the-market equity program, extending revolving loan maturities to April 1, 2030 and increasing borrowing flexibility under tighter leverage and coverage covenants. This combination of longer-dated debt capacity and flexible equity issuance reshapes the REIT’s funding toolkit, potentially affecting how it balances growth, balance sheet strength and future portfolio decisions. Next,...

In early April 2026, UBS upgraded LPL Financial Holdings to Buy, arguing that earlier AI-related concerns were overdone and highlighting the firm’s new partnership with Simplicity Group to broaden insurance solutions for more than 32,000 affiliated advisors overseeing about US$2.40 trillion in client assets. The Simplicity Group agreement, which makes Simplicity LPL’s preferred Brokerage General Agency from May 2026, could deepen LPL’s insurance capabilities and reinforce its position as a...

In early April 2026, investors traded a very large volume of call options on Edison International and several analysts updated their views on the company, while Edison also awarded US$50,000 Edison Scholars scholarships to 30 high school seniors pursuing STEM degrees, funded entirely by its shareholders. Together, the surge in options activity and fresh analyst commentary highlight shifting market expectations for Edison International at the same time the company is emphasizing...

Viridian Therapeutics recently reported positive topline data from its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease, showing statistically significant improvements in eye bulging and double vision with subcutaneous dosing every four or eight weeks versus placebo. Beyond meeting key efficacy endpoints, elegrobart’s low rate of mostly mild, tinnitus-only hearing effects may distinguish it within the anti‑IGF‑1R class as Viridian advances toward a planned Biologics...

Q1 earnings, dividend and board changes set the stage for Nordson (NDSN) Nordson (NDSN) drew fresh investor attention after first quarter fiscal 2026 results met earnings expectations while revenue came in ahead of forecasts, alongside a US$0.82 dividend declaration and new board appointments. See our latest analysis for Nordson. The recent first quarter update appears to be the key driver behind Nordson’s 5.8% 90 day share price return and 54.7% one year total shareholder return, with the...

Why Collegium Pharmaceutical is on investors' radar Collegium Pharmaceutical (COLL) has attracted attention after a period of mixed share performance, including a 4.4% gain over the past week alongside a negative move over the past 3 months and year to date. See our latest analysis for Collegium Pharmaceutical. Despite a 42.89% 1 year total shareholder return, the recent 22.6% 3 month share price decline and softer 30 day share price return suggest momentum has cooled after a strong run. If...

Vornado Realty Trust recently released its 2025 Sustainability Report and furnished its latest Annual Report and Chairman’s Letter, highlighting 100% LEED and WELL Health-Safety certifications across its portfolio and recognition for THE PENN DISTRICT as New York City’s Redevelopment of the Year. Together, these disclosures give investors a fresh window into Vornado’s progress on large redevelopment projects, sustainability priorities, and management’s current expectations for capital...

Jones Lang LaSalle (JLL) at a glance Jones Lang LaSalle (JLL) has drawn fresh attention after recent trading left the shares at $320, with mixed return patterns over the past month and past 3 months prompting closer scrutiny from real estate focused investors. See our latest analysis for Jones Lang LaSalle. The recent 8.27% 1 month share price return contrasts with an 8.58% 3 month share price decline, while the 1 year total shareholder return of 50.02% points to momentum that has built up...

Earlier this week, Loews drew attention after its key subsidiary CNA Financial announced a 4% increase to its regular dividend and a special dividend on April 7, 2026, highlighting strong cash generation and management confidence at the insurance unit. The subsequent reassessment of this dividend news against a backdrop of choppy sentiment toward financial stocks has turned CNA’s payout decision into a broader gauge of how investors are weighing income potential against sector-wide...

In recent days, Dutch Bros has drawn fresh attention as multiple research firms initiated or upgraded coverage while the company continued rolling out new drive-thru locations across high-growth U.S. markets. This combination of favorable analyst commentary and evidence of disciplined expansion, underpinned by a highly penetrated loyalty program, has sharpened investor focus on the brand’s scalability and customer engagement. Now we’ll explore how this reinforced focus on disciplined unit...

In early April 2026, Oscar Health drew attention after CEO Mark Bertolini bought 1,000,000 shares for US$11.92 million and regulators finalized 2027 Medicare Advantage reimbursement increases that will add more than US$13.00 billion in payments across the industry. The combination of a rare insider purchase amid prior insider selling and policy-driven revenue tailwinds for managed-care players is prompting investors to reassess Oscar Health’s longer-term positioning and risk-reward...

Peoples Bancorp (PEBO) has drawn fresh attention after its share price moved above its long term average. This coincides with steadier banking sector conditions and renewed focus on the stock’s dividend and earnings outlook. See our latest analysis for Peoples Bancorp. The latest move above its long term average comes on top of a 9.19% 1 month share price return and a 12.49% 3 month share price return. The 1 year total shareholder return of 35.73% and 3 year total shareholder return of 60.23%...

Dubai launch puts Apollo Go in global focus Baidu (BIDU) is in the spotlight after Apollo Go launched a fully driverless commercial ride hailing service in Dubai, its first international app deployment and a key test of investor appetite for the stock. See our latest analysis for Baidu. Despite the Dubai launch drawing fresh attention to Apollo Go, Baidu’s share price has had a weaker patch, with a 1-month share price return of 13.76% and a year to date share price return of 27.99%. The...

Amylyx Pharmaceuticals recently saw increased analyst attention after the FDA approved its lead therapy AMX0035 for amyotrophic lateral sclerosis, reinforcing its focus on rare neurological diseases. This wave of analyst optimism underscores how regulatory progress on AMX0035 may influence expectations for Amylyx’s broader pipeline and long-term business potential. We’ll now explore how this renewed analyst confidence following AMX0035’s FDA approval could influence Amylyx Pharmaceuticals’...

ERP issues and legal investigation put DNOW (DNOW) under closer scrutiny DNOW (DNOW) is in focus after the Portnoy Law Firm began probing potential securities fraud, following the company’s disclosure that a new Enterprise Resource Planning system created operational issues and financial impacts. See our latest analysis for DNOW. At a share price of US$12.25, DNOW has seen a 5.33% 30 day share price return but a 9.73% 90 day share price decline. The 1 year total shareholder return of 18.82%...